On May 16th, the 2024 annual general meeting of shareholders of Jingjing Pharmaceutical was successfully held. The meeting was chaired by Chairman Li Binshui. During the meeting, Chairman Li Binshui provided a comprehensive overview of the company's operations for 2024 and the work plan for 2025. He also focused on the company's latest developments, new product research and development, future development strategies, technological innovations, talent cultivation, and market prospects. After the meeting, the company's general manager had in-depth discussions with the shareholders regarding the production and sales of the company's anti-aging products and market prospects. Through these discussions, the shareholders gained a clearer understanding of the company's development strategy and operational situation, which further strengthened their trust in Jingjing Pharmaceutical and their expectations for the future. In an industry where competition is fierce and the market environment is complex and dynamic, Jingjing Pharmaceutical will maintain a high level of enthusiasm and determination, stay focused on its goals, and work steadily towards them. By enhancing technological innovation to seek breakthroughs, the company will continue to focus on creating value for its customers, continuously optimize its products and services, and explore new paths for growth in this complex environment. This will enable the company to create even greater value for its shareholders and inject new momentum into the industry's development.